91��

These are press releases sent out by the companies.
Questions and comments should be sent to the company directly.

91�� BioCapital Portfolio News

17 June 2026

SYNAPSE-CMT Phase 2a Clinical Study Data Presented in Late-Breaking Oral Presentation at 2026 PNS Annual Meeting
91�� BioCapital Portfolio News

10 March 2026

NMD Pharma late-breaking oral presentation at MDA with top-line safety and efficacy data from the SYNAPSE-CMT Phase 2a study of ignaseclant in Charcot-Marie-Tooth disease types 1 and 2
91�� BioCapital Portfolio News

9 March 2026

Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough
91�� BioCapital Portfolio News

12 February 2026

NMD Pharma results from Phase 2a study of ignaseclant in Charcot-Marie-Tooth disease Types 1 and 2 selected for late-breaking oral presentation at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
91�� BioCapital Portfolio News

7 January 2026

NMD Pharma to present at the 44th Annual J.P. Morgan Healthcare Conference
91�� BioCapital Portfolio News

16 December 2025

IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications
91�� BioCapital Portfolio News

9 December 2025

Enterome presents strengthened interim Phase 2 results for lead OncoMimics™ immunotherapy EO2463 to treat follicular lymphoma at ASH •
91�� BioCapital Portfolio News

19 November 2025

Kvantify Releases Transformative Chemistry Software Qrunch for Quantum Computers
91�� BioCapital Portfolio News

14 November 2025

Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
Vesper Bio

31 October 2025

Vesper Bio announces positive Phase Ib/IIa topline results for lead candidate VES001 for frontotemporal degeneration
Acquisition of scPharmaceuticals

7 October 2025

MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care
91�� BioCapital Portfolio News

29 September 2025

IO Biotech Provides Update Following Pre-BLA Meeting with FDA
91�� BioCapital Portfolio News

23 September 2025

IO Biotech Announces Late-Breaking Abstract in Advanced Melanoma Selected for Oral Presentation at ESMO Congress 2025
91�� BioCapital Portfolio News

3 September 2025

NMD Pharma Expands Senior Leadership Team with the Appointment of Ana de Vera as Chief Medical Officer
91�� BioCapital Portfolio News

13 August 2025

Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update
91�� BioCapital Portfolio News

11 August 2025

IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed
91�� BioCapital Portfolio News

7 August 2025

SNIPR BIOME Raises EUR 35 Million Series B Financing to Advance CRISPR-Medicines Targeting Antimicrobial Resistance
91�� BioCapital Portfolio News

12 June 2025

SNIPR BIOME Announces First Patient Dosed in its Phase 1b Clinical Trial of SNIPR001 in Patients with Hematological Cancer
91�� BioCapital Portfolio News

6 June 2025

Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
91�� BioCapital Portfolio News

28 May 2025

Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee
91�� BioCapital Portfolio News

14 May 2025

IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights
91�� BioCapital Portfolio News

14 May 2025

Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update
91�� BioCapital Portfolio News

26 April 2025

IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025
91�� BioCapital Portfolio News

25 April 2025

IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170
91�� BioCapital Portfolio News

28 March 2025

Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update
91�� BioCapital Portfolio News

26 March 2025

IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting
91�� BioCapital Portfolio News

25 March 2025

NMD Pharma presents preclinical data highlighting increased innervation of skeletal muscle with ClC-1 ion channel inhibition treatment in neuromuscular disease model
91�� BioCapital Portfolio News

18 March 2025

IO Biotech Named Among Fast Company’s World’s Most Innovative Companies of 2025
91�� BioCapital Portfolio News

5 March 2025

IO Biotech Reports 2024 Business Highlights
91�� BioCapital Portfolio News

4 February 2025

IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate